Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis
K Tanaka, T Kanno, Y Yanagisawa, K Yasutake… - Experimental …, 2011 - Elsevier
K Tanaka, T Kanno, Y Yanagisawa, K Yasutake, S Hadano, F Yoshii, JE Ikeda
Experimental neurology, 2011•ElsevierAmyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease
characterized by a selective loss of upper and lower motor neurons. Since oxidative stress
plays a crucial role in the progression of motor neuron loss observed in ALS, anti-oxidative
agents could be an important therapeutic means for the ALS treatment. We have previously
developed a drug screening system allowing the identification of small chemical compounds
that upregulate endogenous neuronal apoptosis inhibitory protein (NAIP), an oxidative …
characterized by a selective loss of upper and lower motor neurons. Since oxidative stress
plays a crucial role in the progression of motor neuron loss observed in ALS, anti-oxidative
agents could be an important therapeutic means for the ALS treatment. We have previously
developed a drug screening system allowing the identification of small chemical compounds
that upregulate endogenous neuronal apoptosis inhibitory protein (NAIP), an oxidative …
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease characterized by a selective loss of upper and lower motor neurons. Since oxidative stress plays a crucial role in the progression of motor neuron loss observed in ALS, anti-oxidative agents could be an important therapeutic means for the ALS treatment. We have previously developed a drug screening system allowing the identification of small chemical compounds that upregulate endogenous neuronal apoptosis inhibitory protein (NAIP), an oxidative stress-induced cell death suppressor. Using this system, we identified the dopamine D2 receptor agonist bromocriptine (BRC) as one of NAIP-upregulating compounds. In this study, to prove the efficacy of BRC in ALS, we conducted a set of preclinical studies using a transgenic ALS mouse model carrying the H46R mutation in the human Cu/Zn superoxide dismutase (SOD1) gene ALS(SOD1H46R) by the post-onset administration of BRC. ALS(SOD1H46R) mice receiving BRC showed sustained motor functions and modest prolonged survival after onset. Further, BRC treatment delayed anterior horn cell loss, and reduced the number of reactive astrocytes and the level of inflammatory factors such as inducible nitric oxide synthase (iNOS) and tumor necrosis factor (TNF)-α in the spinal cord of late symptomatic mice. In vitro study showed the reduced level of extracellular TNF-α after lipopolysaccharide (LPS) exposure in BRC-treated mouse astrocytes. BRC-treated ALS(SOD1H46R) mice also showed a reduced level of oxidative damage in the spinal cord. Notably, BRC treatment resulted in an upregulation of anti-oxidative stress genes, activating transcription factor 3 (ATF3) and heme oxygenase-1 (HO-1), and the generation of a glutathione (GSH) in SH-SY5Y cultured neuronal cells in a dopamine receptor-independent manner. These results imply that BRC protects motor neurons from the oxidative injury via suppression of astrogliosis in the spinal cord of ALS(SOD1H46R) mice. Thus, BRC might be a promising therapeutic agent for the treatment of ALS.
Elsevier